Sovaldi

January 20, 2015January 20, 2015

Report Indicates Higher Prescription Rates of Two Novel Hepatitis C Therapies, Increase in Treated Patients

Hepatitis C, News

Recently, the CVS Health Research Institute analyzed the rate of prescriptions for two novel hepatitis C treatments, Harvoni® (ledipasvir and sofosbuvir) and Sovaldi® (sofosbuvir) a few weeks after their respective ... Read more

January 14, 2015January 14, 2015

Hepatitis C Patients Protest Limited Access to Sofosbuvir

News

Hundreds of hepatitis C patients and respective supporters protested in Madrid last December, complaining about the cuts in public spending that have significantly reduced public access to Sovaldi (sofosbuvir), a ... Read more

December 10, 2014December 10, 2014

Lawsuit Against Gilead Sciences High Prices For Sovaldi In The U.S.

Hepatitis C, News

A lawsuit was recently filed by a Philadelphia-area law firm against Gilead Sciences, Inc. (“Gilead”) on behalf of the Southeastern Pennsylvania Transportation Authority (“SEPTA”) due to the sale and pricing of Sovaldi®, Gilead’s groundbreaking Hepatitis C drug. Sovaldi is ... Read more

October 29, 2014October 29, 2014

Patient Population Eligible for Hepatitis C Treatment Limited by High Costs

Hepatitis C, News

Despite the hope generated by more efficacious, safer hepatitis C drugs within the past years, a number of patients with the chronic liver disease may not qualify for access to ... Read more

October 21, 2014October 22, 2014

Sovaldi Better for Cost Issues in Hep C Treatments for Inmates

Hepatitis C, News

The treatment of inmates remains a hot-button issue that includes a wide range of different considerations, ranging from how well cared-for a prisoner should be to the economics involved in maintaining ... Read more